Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID‐19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N‐hydroxycytidine with an in vitro and in vivo activity against...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology Vol. 94; no. 11; pp. 5582 - 5588
Main Authors: De Vito, Andrea, Colpani, Agnese, Bitti, Alessandra, Zauli, Beatrice, Meloni, Maria Chiara, Fois, Marco, Denti, Lucia, Bacciu, Sara, Marcia, Claudia, Maida, Ivana, Babudieri, Sergio, Madeddu, Giordano
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01-11-2022
John Wiley and Sons Inc
Subjects:
Aged
Aged, 80 and over
Antiviral drugs
antiviral treatment
Comorbidity
Coronaviruses
COVID-19
COVID-19 Drug Treatment
COVID‐19 treatment
Cytidine - analogs & derivatives
Disease
Disease Progression
Dyspnea
early treatment
Effectiveness
Health risks
Humans
Hydroxylamines
In vivo methods and tests
Middle Aged
molnupiravir
Multivariate analysis
Neurological diseases
Pandemics
Patients
Respiration
Respiratory diseases
Retrospective Studies
Risk assessment
Risk management
Safety
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Short Communication
Short Communications
Signs and symptoms
Supplements
Viral diseases
Virology
COVID-19
antiviral treatment
COVID-19 treatment
SARS-CoV-2
molnupiravir
early treatment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) pandemic, several treatments have been proposed to cure coronavirus disease 2019 (COVID‐19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N‐hydroxycytidine with an in vitro and in vivo activity against SARS‐CoV‐2. We conducted a retrospective cohort study that included all people treated with molnupiravir between January 10, 2022, and March 31, 2022, at the University Hospital of Sassari. Molnupiravir was prescribed, according to the Italian Agency of Drug indications, to patients with recent symptom onset (≤5 days), no need for oxygen supplementation, and with a high risk of disease progression for the presence of chronic diseases. We included 192 people with a mean age of 70.4 ± 15.4 years, with 144 (75%) patients over 60 years. During the follow‐up, 20 (10.4%) patients showed a disease progression. At the multivariate analysis, older age, having neurological disease, having dyspnea at the onset of the symptoms, and acquiring SARS‐CoV‐2 infection during hospital admission were associated with an increased risk of progression. In contrast, an early start of treatment was associated with a reduced risk of disease progression. Molnupiravir was also extremely safe since 13 (6.8%) adverse events were reported, with only one interruption. Our study shows that monlupiravir confirmed its efficacy and safety in a real‐life cohort that included a high percentage of elderly people with a high comorbidity burden.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.28011